Life Sciences

MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros

• Medlumics has closed a round of financing round of 34,4 million euros to bring their main product into the market, AblaView, an atrial fibrillation treatment in the field of cardiac arrhythmias.
• Medlumics is a company dedicated to medical technology for the treatment of cardiac diseases, with products based on photonic energy.
• Caixa Capital Risc and Ysios Capital invested in Medlumics in 2012 to support the company in its development.
• This has been the largest round in the history of the medical technology industry in Spain, and one of the largest in Europe.

| Read more |

Transplant Biomedicals closes first investment in health of 2017 in Spain, €2.5 million

Caixa Capital Risc and Kereon Partners invest in spin-off created from
IDIBAPS-Hospital Clinic Barcelona technology transfer
The company will begin clinical trials on a device to improve the quality and
viability of kidney and liver transplants, which are the most common types in
Spain (2,905 and 1,162 respectively in 2015)
6 in 10 organs transplanted fail for various reasons, including current
transport storage methods (in picnic-style coolers)
Transplant Biomedicals has now raised more private capital than any other
non-diagnostic medical device company in Spain

| Read more |

The “la Caixa” Foundation and “Caixa Capital Risc” open calls for applications for the CaixaImpulse program to promote the creation of new biotechnological engineering companies.

EIT Health, leading European consortium for innovation in biomedicine, collaborates in this edition of the pioneering program.

engineering companies.

• Tomorrow, the third call for applications for the CaixaImpulse program will be re-opened. This initiative of the “la Caixa” Foundation and Caixa Capital Risc will also have the support of EIT Health, the leading European consortium for innovation, research centres and innovation companies in the fields of biomedicine and health.

• This year’s edition will include two novelties: the call will be opened to Portugal and the number of beneficiaries will grow from 20 to 23.

• Projects can be presented to the program until the 15th of March, by Spanish and Portuguese research centres that are owners or co-owners of protected assets or are in the process of being so in the field of life science and health.

• Caixaimpulse is the first integrated program in Spain and Portugal for the transformation of scientific knowledge originated in research centres, universities and hospitals, into companies and products that will generate value to society, either in the form of a spin-off or a transfer agreement.

• The CaixaImpulse program will allocate over 2 million euros to the iniative. The selected projects will receive a financial benefit of up to 70.000 euros, destined to define and execute a valuation plan of the technology with the highest probability of success, as well as an eight-month expert support program valued in 300.000 euros, led by mentors, specialists, entrepreneurs, and internationally renowned educators.

| Read more |

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

MIN-102, a differentiated PPAR agonist, targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with a high unmet medical need

– Trial will assess pharmacokinetics, safety and tolerability of MIN-102 after administration of single and multiple ascending doses in healthy volunteers.

| Read more |

(Español) Minoryx Therapeutics nombra al Dr. Uwe Meya como Director Médico

(Español) El Dr. Meya, especialista en trastornos neurológicos, dirigirá el desarrollo clínico del principal candidato de Minoryx, el MIN-102, para la X-ALD.

| Read more |